Skip to Content

Imara Inc.

Merger

  • Date:
  • 10/13/2022
  • Company Name:
  • Imara Inc.
  • Stock Symbol:
  • IMRA
  • Company Name - Buyer:
  • Enliven Therapeutics, Inc.
  • Status:
  • Investigating
  • Merger Announcement Date:
  • 10/13/2022

Case Finder

Locate any case using the tools below.

NEW YORK, October 13, 2022 – Bragar Eagel & Squire, P.C., a nationally recognized stockholder rights law firm, has launched an investigation into whether the officers or directors of Imara Inc. (NASDAQ: IMRA) (“Imara”) breached their fiduciary duties or violated the federal securities laws in connection with the company’s acquisition by Enliven Therapeutics, Inc. (“Enliven”).

On October 13, 2022, Imara announced that it had entered into an agreement to be acquired by Enliven in an all stock deal. Pursuant to the merger agreement, Imara will issue to pre-merger Enliven stockholders shares of Imara common stock as merger consideration in exchange for the cancellation of shares of capital stock of Enliven and Enliven will become a wholly-owned subsidiary of Imara. Pre-merger Imara stockholders are expected to own approximately 16% of the combined company and pre-merger Enliven stockholders (including those purchasing Enliven shares in the private financing discussed above) are expected to own approximately 84% of the combined company. The deal is expected to close in the first quarter of 2023.

Bragar Eagel & Squire is concerned that Imara’s board of directors oversaw an unfair process and ultimately agreed to an inadequate merger agreement. Accordingly, the firm is investigating all relevant aspects of the deal and is committed to securing the best result possible for Imara’s stockholders.
The individual or institution below (“Plaintiff”) has reviewed and agrees to the Bragar Eagel & Squire, P.C. (“BESPC”) retainer agreement and authorizes BESPC to prosecute an action on Plaintiff’s behalf under the federal securities laws or applicable state laws to recover damages on behalf of investors in Imara Inc.. BESPC will prosecute the action on a full contingency basis and will forward all costs and expenses.
 

Case Finder

Locate any case using the tools below.

You may share a link to this page on any of the sites listed below or send link via email: